Cancer Research and Clinical Trials
at
Calvary Central Districts and Calvary North Adelaide Hospitals
at
Calvary Central Districts and Calvary North Adelaide Hospitals
The Calvary Cancer Clinical Trials and Research Centre is based at the Calvary Central Districts and Calvary North Adelaide Hospitals in Elizabeth Vale and North Adelaide. The Research Centre is setup in collaboration and partnership with multiple large and small cancer research organisations.
Cancer Research Director: Dr Rohit Joshi
Cancer Trials Manager: Dr Julie Rowe
The Calvary Cancer Research Centre is affiliated to Cancer Trials Australia.
Cancer Research Director: Dr Rohit Joshi
Cancer Trials Manager: Dr Julie Rowe
The Calvary Cancer Research Centre is affiliated to Cancer Trials Australia.
List of Clinical Trials open at Calvary Hospitals:
Lung Cancer (PI: Dr Rohit Joshi)
A multicentre, double blind, randomized, controlled study of M7824 with concurrent chemo-radiation followed by M7824 versus concurrent chemo- radiation plus placebo followed by durvalumab in participants with un- resectable stage III NSCLC
Colorectal Cancer (PI: Dr Rohit Joshi)
A phase 2 clinical trial of Nivolumab versus Ipilimumab and Nivolumab versus Chemotherapy in metastatic microsatellite instability high (MSI-H) colorectal cancer
Kidney Cancer (PI: Dr Rohit Joshi)
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Urinary Bladder Cancer (PI: Dr Rohit Joshi)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
Melanoma (PI: Dr Rachel Roberts-Thomson)
A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Breast Cancer (PI: Dr Rohit Joshi)
A phase 2, open-label study of intratumoural tavokinogene telseplasmid plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple negative breast cancer.
Lung Cancer (PI: Dr Rohit Joshi)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (Retrospective data collection from patients treated with durvalumab via EAP)
Supportive Care: Any Cancer Type (PI: Dr Rohit Joshi)
A Smartphone Text Message Self-Management Program to Support Adequate Adherence to Oral Chemotherapy in AYA and Adult Cancer Patients: Proof-Of-Concept.
Lung Cancer (PI: Dr Rohit Joshi)
A multicentre, double blind, randomized, controlled study of M7824 with concurrent chemo-radiation followed by M7824 versus concurrent chemo- radiation plus placebo followed by durvalumab in participants with un- resectable stage III NSCLC
Colorectal Cancer (PI: Dr Rohit Joshi)
A phase 2 clinical trial of Nivolumab versus Ipilimumab and Nivolumab versus Chemotherapy in metastatic microsatellite instability high (MSI-H) colorectal cancer
Kidney Cancer (PI: Dr Rohit Joshi)
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Urinary Bladder Cancer (PI: Dr Rohit Joshi)
A Phase 3, Randomized, Study of Neoadjuvant Chemotherapy alone versus Neoadjuvant Chemotherapy plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Post-Surgery Therapy with Nivolumab or Nivolumab and BMS-986205 in Participants with Muscle-Invasive Bladder Cancer
Melanoma (PI: Dr Rachel Roberts-Thomson)
A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Breast Cancer (PI: Dr Rohit Joshi)
A phase 2, open-label study of intratumoural tavokinogene telseplasmid plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple negative breast cancer.
Lung Cancer (PI: Dr Rohit Joshi)
First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (Retrospective data collection from patients treated with durvalumab via EAP)
Supportive Care: Any Cancer Type (PI: Dr Rohit Joshi)
A Smartphone Text Message Self-Management Program to Support Adequate Adherence to Oral Chemotherapy in AYA and Adult Cancer Patients: Proof-Of-Concept.